Abstract：
:Cancer is a disease in which cellular growth regulatory networks are disrupted. Lesions in well-characterized oncogenes and tumor suppressors often contribute to the dysregulation, but recent work has also uncovered the fundamental importance of enzymes that modulate the acetylation status of chromatin to the initiation or progression of cancer. Histone acetyltransferases (HATs) and histone deacetylases (HDACs) are known to be involved in physiological cellular processes, such as transcription, cell cycle progression, gene silencing, differentiation, DNA replication, and genotoxic responses, but they are also increasingly being implicated in tumorigenesis. Butyrate is a short-chain fatty acid (SCFA) that acts as a HDAC inhibitor and is being clinically evaluated as an anti-neoplastic therapeutic, primarily because of its ability to impose cell cycle arrest, differentiation, and/or apoptosis in many tumor cell types, and its favorable safety profile in humans. Additionally, HDAC inhibitors could be used in combination with certain established antitumor therapeutics, such as those that target transcription, to augment clinical efficacy, and/or reduce toxicity. The molecular pathways of butyrate and related next-generation synthetic SCFAs in mediating these effects have not been fully elucidated, but HDAC inhibition is associated with regulation of critical cell cycle regulators, such as cyclin D, p21(CIP1/WAF1), and p27(KIP1). It is anticipated that a better understanding of this critical intersection between SCFAs, HDACs, and cell cycle control will lead to the design of novel treatment strategies for neoplasias. This review will summarize some of the recent research in these arenas of HDAC-directed cancer therapy and discuss the potential application of these agents in synergy with current chemotherapeutics.
journal_name
Curr Cancer Drug Targetsjournal_title
Current cancer drug targetsauthors
Chen JS,Faller DV,Spanjaard RAdoi
10.2174/1568009033481994keywords:
subject
Has Abstractpub_date
2003-06-01 00:00:00pages
219-36issue
3eissn
1568-0096issn
1873-5576journal_volume
3pub_type
杂志文章,评审abstract：:Actin was first identified in non-muscle cells only about three decades ago, and at about the same time, it was found that actin filaments were disrupted in the malignant transformed cells. The actin network is a rather complex, yet important structural and functional system of all eukaryotic cells. Actin filaments pr...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/1568009043332998
更新日期：2004-06-01 00:00:00
abstract：:Androgen deprivation therapy has been the major treatment for advanced prostate cancer (PCa) and has shown to prolong life. However, remissions are temporary and patients almost inevitably progress to become castration-resistant prostate cancer (CRPC). CRPC is almost incurable even when treated with docetaxel that may...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800910791208544
更新日期：2010-06-01 00:00:00
abstract：:NUPR1 is a transcription factor that has attracted great attention because of its various roles in cancer. Several studies were carried out to determine its molecular targets and mechanism of action to develop novel therapies against cancer. Here, we shed light on the role of NUPR1 in different types of cancer. NUPR1 ...
journal_title：Current cancer drug targets
pub_type： 杂志文章
doi：10.2174/1568009620666200703152523
更新日期：2020-01-01 00:00:00
abstract：:MicroRNAs (miRNAs) control the expression of approximately 60% of protein-coding genes and regulate cell metabolism, proliferation, differentiation, and apoptosis. Notably, aberrant expression of miRNAs contributes to several diseases including cancer. Accumulating evidence indicates that miRNAs play important roles i...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/1568009616666160216130608
更新日期：2017-01-01 00:00:00
abstract：:One of the crucial reasons of breast cancer therapy failure is an impairment of mechanisms responsible for metabolism and cellular homeostasis, which makes it difficult to foresee the response to the treatment. Targeted therapy in breast cancer is dictated by the expression of specific molecules such as growth factor ...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/1568009617666171114143330
更新日期：2018-01-01 00:00:00
abstract：:Polyisoprenylated proteins (PPs) methylation by polyisoprenylated protein methyl transferase (PPMTase) is counteracted by polyisoprenylated methylated protein methyl esterase (PMPMEase). This is the only reversible step of the polyisoprenylation pathway as the relative amounts of the acid and ester forms are determine...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800910791859443
更新日期：2010-09-01 00:00:00
abstract：BACKGROUND:Oncolytic viruses (OVs), which preferentially infect cancer cells and induce host anti-tumor immune responses, have emerged as an effective melanoma therapy. Tanapoxvirus (TANV), which possesses a large genome and causes mild self-limiting disease in humans, is potentially an ideal OV candidate. Interleukin-...
journal_title：Current cancer drug targets
pub_type： 杂志文章
doi：10.2174/1568009617666170630143931
更新日期：2018-01-01 00:00:00
abstract：:Lipophilic derivatives of the anticancer drug paclitaxel (PTX) were prepared by means of its conjugation to lipoamino acid (LAA) residues, with the aim of increasing drug accumulation in tumor cells. PTX was linked to the methyl esters of norleucine (C6) or 2-aminodecanoic acid (C10). A succinic acid group was used as...
journal_title：Current cancer drug targets
pub_type： 杂志文章
doi：10.2174/156800909787580944
更新日期：2009-03-01 00:00:00
abstract：:The application of nanotechnology to biomedical research is expected to have a major impact leading to the development of new types of diagnostic and therapeutic tools. One focus in nanobiotechnology is to develop safe and efficient drug/gene delivery vehicles. Research into the rational delivery and targeting of phar...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800911794328411
更新日期：2011-02-01 00:00:00
abstract：:(5Z,9Z)-11-Phenylundeca-5,9-dienoic acid was stereoselectively synthesized, based on original cross-cyclomagnesiation of 2-(hepta-5,6-dien-1-yloxy)tetrahydro-2H-pyran and buta-2,3-dien-1-ylbenzene with EtMgBr in the presence of the Cp2TiCl2 catalyst giving 2,5-dialkylydenemagnesacyclopentane in 86% yield. The acid hyd...
journal_title：Current cancer drug targets
pub_type： 杂志文章
doi：10.2174/1568009615666150506093155
更新日期：2015-01-01 00:00:00
abstract：:FOXO proteins are evolutionarily conserved transcription factors implicated in several fundamental cellular processes, functioning as end-point for transcriptional programs involved in apoptosis, stress response and longevity. Abrogation of FOXO function is very frequent in human cancer, therefore the mechanisms of re...
journal_title：Current cancer drug targets
pub_type： 杂志文章
doi：10.2174/156800910791054158
更新日期：2010-03-01 00:00:00
abstract：:Angiotensin II (Ang II), a main effector peptide of the renin-angiotensin system (RAS), mediates a hormonal action in the maintenance of blood pressure and electrolyte levels, and thus fluid homeostasis. Ang II also mediates paracrine, autocrine and/or intracrine actions in the control of various specific functions of...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800911795538110
更新日期：2011-05-01 00:00:00
abstract：:Hepatocellular carcinoma (HCC), considered to be one of the most lethal cancers with almost > 1 million deaths reported annually worldwide, remains a devastating disease with no known effective cure. Hence, chemopreventive strategies come into play, offering an effective and safe mode of treatment, ideal to ward off p...
journal_title：Current cancer drug targets
pub_type： 杂志文章
doi：10.2174/156800912803987968
更新日期：2012-11-01 00:00:00
abstract：:The potential clinical applications of the prototype first-in-class Hsp90 inhibitor 17AAG and other emerging Hsp90 drugs are very exciting. Rigorously planned and executed clinical trials, incorporating measurement of appropriate biomarkers and pharmocodynamic endpoints are critical for selecting the optimal dose and ...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/1568009033481813
更新日期：2003-10-01 00:00:00
abstract：BACKGROUND AND AIM:Translational data suggest that nucleoside transporters, in particular human equilibrative nucleoside transporter 1 (hENT1), play an important role in predicting clinical outcome after gemcitabine chemotherapy for several types of cancer. The aim of this study was to retrospectively determine patient...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800911793743600
更新日期：2011-01-01 00:00:00
abstract：:Heat shock protein 32 (Hsp32), also known as heme oxygenase-1 (HO-1), is a stress-related anti-apoptotic molecule, that has been implicated in enhanced survival of neoplastic cells and in drug-resistance. We here show that Hsp32 is expressed in most solid tumors and hematopoietic neoplasms and may be employed as a new...
journal_title：Current cancer drug targets
pub_type： 杂志文章
doi：10.2174/156800909789057024
更新日期：2009-08-01 00:00:00
abstract：BACKGROUND:Current gene therapy vectors such as viral, non-viral, and bacterial vectors, which are used for cancer treatment, but there are certain safety concerns and stability issues of these conventional vectors. Exosomes are the vesicles of size 40-100 nm secreted from multivesicular bodies into the extracellular e...
journal_title：Current cancer drug targets
pub_type： 杂志文章
doi：10.2174/1568009620666200924154149
更新日期：2020-01-01 00:00:00
abstract：:Castration-resistant prostate cancer remains incurable and a major cause of mortality worldwide. The absence of effective therapeutic approaches for advanced prostate cancer has led to an intensive search for novel treatments. Emerging nanomedical approaches have shown promising results, in vitro and in vivo, in impro...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800911797264770
更新日期：2011-10-01 00:00:00
abstract：:Cell-penetrating peptides (CPPs) have been previously shown to be powerful transport vector tools for the delivery of a large variety of cargoes through the cell membrane, as well as other physiological membranes. And since they're relatively cell-, receptor- and energy-independent, CPPs have unique advantages in faci...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/1568009615666150211104524
更新日期：2015-01-01 00:00:00
abstract：:Ovarian cancer is a leading cause of death worldwide from gynecological malignancies, mainly because there are few early symptoms and the disease is generally diagnosed at an advanced stage. In addition, despite the effectiveness of cytoreductive surgery for ovarian cancer and the high response rates to chemotherapy, ...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/1568009618666181010091246
更新日期：2019-01-01 00:00:00
abstract：:Preferentially expressed antigen in melanoma (PRAME) is the best characterized member of the PRAME family of leucine-rich repeat (LRR) proteins. Mammalian genomes contain multiple members of the PRAME family whereas in other vertebrate genomes only one PRAME-like LRR protein was identified. PRAME is a cancer/testis an...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/1568009616666151222151818
更新日期：2016-01-01 00:00:00
abstract：:One of the older and most validated cancer treatments is endocrine therapy. Some tumors are dependent on hormone stimulation for growth, and therefore therapeutic interventions aiming to deprive the cells of the hormone are feasible and have been successful. Tumor growth also depends in some cases on growth factors, s...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800907780618310
更新日期：2007-05-01 00:00:00
abstract：BACKGROUND:Improving poorly soluble drugs into druggability was a major problem faced by pharmaceutists. Nanosuspension can improve the druggability of insoluble drugs by improving the solubility, chemical stability and reducing the use of additives, which provided a new approach for the development and application of ...
journal_title：Current cancer drug targets
pub_type： 杂志文章
doi：10.2174/1568009618666180629150927
更新日期：2019-01-01 00:00:00
abstract：BACKGROUND:CYP1B1 is recognized as a valuable target for chemotherapy. It catalyzes the bioactivation of naphthoquinone oximes within certain cancer cell lines. However, the expression level of CYP1B1 in melanoma and the functional role regulating the activity of DMAKO-20 as a representative naphthoquinone oxime agains...
journal_title：Current cancer drug targets
pub_type： 杂志文章
doi：10.2174/1568009620666201116112937
更新日期：2020-11-15 00:00:00
abstract：:As microtubules are essential in many cell functions, they have been used as a target of a variety of anticancer drugs that are grouped as stabilizing (taxanes) and destabilizing (vinca-alkaloids, colchicinoids) microtubule agents. It appears clearly now that the dynamic behaviour more than modifications of microtubul...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800907783220426
更新日期：2007-12-01 00:00:00
abstract：:Membrane ion channels participate in cancerous processes such as proliferation, migration and invasion, which contribute to metastasis. Increasing evidence indicates that voltage-dependent K(+) (Kv) channels are involved in the proliferation of many types of cells, including tumor cells. Kv channels have generated imm...
journal_title：Current cancer drug targets
pub_type： 杂志文章
doi：10.2174/156800909790192400
更新日期：2009-12-01 00:00:00
abstract：:Amplification of the HER-2 gene occurs in approximately 25% of breast cancers, causing up-regulation of key signaling pathways which control cell growth and survival. In breast cancer patients, HER-2 overexpression correlates with an aggressive phenotype and poor prognosis. HER-2, therefore, has become the focus of ma...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800909788166484
更新日期：2009-05-01 00:00:00
abstract：:Prevention is one of the most important and promising strategies to control cancer. Many dietary bioactive compounds, mostly phytochemicals, have been found to decrease the risk of carcinogenesis. Modulating the metabolism and disposition pathways of carcinogens represents one of the major mechanisms by which dietary ...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800907781386669
更新日期：2007-08-01 00:00:00
abstract：:Human mesenchymal stem cells (hMSCs) consist of cells that can differentiate into mesenchymal tissues, including osteoblasts, adipocytes and chondrocytes. hMSCs constitute a particular stem cell niche in the stromal compartment of the bone marrow, and also play a role in maintaining the normal function of haematopoiet...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800910791208553
更新日期：2010-06-01 00:00:00
abstract：:Polysialic acid (polySia) is a carbohydrate polymer critical for neuronal cell migration and axon pathfinding in embryonic development. Besides brain regions requiring persistent neuronal plasticity, polySia is essentially absent from the adult body. However, polySia is aberrantly re-expressed on many tumours, where i...
journal_title：Current cancer drug targets
pub_type： 杂志文章,评审
doi：10.2174/156800912803251225
更新日期：2012-10-01 00:00:00
